The global cardiac biomarkers market size was valued at USD 18.62 billion in 2024. The market is projected to grow from USD 20.90 billion in 2025 to USD 47.43 billion by 2032, exhibiting a CAGR of 12.4% during the forecast period. Cardiac biomarkers are proteins, enzymes, or hormones released into the bloodstream when the heart muscle is damaged or under stress. They are essential for diagnosing and monitoring cardiovascular conditions such as acute coronary syndrome (ACS), myocardial infarction, and heart failure. These biomarkers help clinicians quickly assess the severity of cardiac events and improve patient outcomes through timely intervention.
Get a Free Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cardiac-biomarkers-market-101233
Increasing Cardiovascular Disease Burden
Lifestyle changes, aging demographics, and risk factors like diabetes, hypertension, and obesity are fueling the rise of cardiovascular diseases globally.
Growing Adoption of Point-of-Care Testing
Portable and rapid point-of-care (POC) cardiac tests are transforming emergency care by providing swift, accurate results without needing central laboratory infrastructure.
Technological Advancements
High-sensitivity assays (especially for troponin and BNP) offer early detection and better accuracy, supporting improved clinical decision-making.
Limited Availability of POC Tests in Developing Markets
While demand is high, access to advanced rapid tests in low-resource settings remains limited.
Testing Limitations
Certain biomarkers, like CK-MB, require time to elevate after cardiac damage, limiting immediate diagnosis.
Regulatory Challenges & Costs
Testing kits must comply with stringent regulatory standards. High costs for advanced assays limit adoption, especially in emerging economies.
By Indication:
By Biomarker: